Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Blue Mesa Health

- PMLiVE

EU nod for Novo Nordisk’s Tresiba and Ryzodeg

Reduced risk of hypoglycaemia may give insulin products edge ahead of Sanofi’s Lantus

Boehringer, EFSD offer €2.5m in diabetes research grants

Application accepted up until April 1, 2013

- PMLiVE

Sanofi US joins NBA for diabetes awareness drive

Andre Iguodala, Danny Granger and Tamika Catchings sign up as ambassadors for Dribble to Stop Diabetes

Medicine adherence linked to doctor-patient communications

Patients’ trust and confidence in HCP impacts on adherence, according to US study

- PMLiVE

J&J gets FDA panel backing for canagliflozin

Moves ahead of BMS/AZ’s Forxiga in race for US approval as first in new class of diabetes drug

- PMLiVE

Novo Nordisk creates all-diabetes pro-cycling team

Team Novo Nordisk includes more than 100 cyclists, triathletes and runners with diabetes

- PMLiVE

Boehringer and Lilly close in on empagliflozin filing

But amend diabetes alliance after Boehringer drops basal insulin

- PMLiVE

Pharma’s 2012 in … gamification

Boehringer’s headline-grabbing Syrum wasn’t this year's only use of gaming techniques

- PMLiVE

Novo Nordisk says Ryzodeg nears Japanese approval

Combination of Tresiba and NovoRapid expected to compete with Sanofi’s Lantus

- PMLiVE

Depth perception: diabetes in India

Using digital, pharma can engage with diabetes patients in India and build a 3D image of their needs

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

- PMLiVE

NIHR launches online diabetes research showcase

Aims to raise public aware of diabetes and the importance of research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links